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carboplatin plus irinotecan over carboplatin plus etoposide in one 
study (12). Other randomized trials comparing these carboplatin-based 
regimens are being conducted. Furthermore, a phase I trial combining 
cisplatin plus etoposide plus irinotecan resulted in a 77% response rate 
and median survival time of 12 months in 31 evaluable patients from 
Greece (13). Further phase II/III evaluation of this three drug regimen 
are underway. Finally, irinotecan-based therapy is undergoing evalu-
ation in limited stage patients as induction therapy (IP followed by 
concurrent EP and radiation) as well as consolidation therapy (EP and 
concurrent radiation followed by IP) (14,15). Each of these strategies 
resulted in a median survival time of about 2 years in phase II studies.
In conclusion, irinotecan is an active drug against SCLC. The IP 
regimen appears more effective than EP in Asian patient populations, 
although these results have not been conﬁrmed in North American 
populations. A completed phase III study from the Southwest Oncology 
Group in the U.S. comparing IP versus EP, given in the identical dose 
and schedules as the Noda trial, will deﬁnitively address this issue. 
Studies evaluating the role of irinotecan in limited stage disease are 
underway.
References
1. Green RA, Humphrey E, Close H, Patno ME. Alkylating agents in bronchogenic carci-
noma. Am J Med 1969;46:516-525.
2. Roth B, Johnson D, Einhorn L, et al. Randomized Study of Cyclophosphamide, Doxo-
rubicin, and Vincristine versus Etoposide and Cisplatin versus Alternation of These Two 
Regimens in Extensive Small-Cell Lung Cancer: a Phase III Trial of the Southeastern 
Cancer Study Group. J Clin Oncol 1992;10:282-291.
3. Wall M, Wani M, Cook C, et al. Plant antitumor agents, I: the isolation and structure 
of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca 
acuminate. J Am Chem Soc 1966; 88:3888-90.
4. Hsiang Y, Hertzberg R, Hecht S, et al. Camptothecin induces protein-linked DNA 
breaks in mammalian DNA topoisomerase I. J Biol Chem 1985;260:14873-78.
5. Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinote-
can disposition and toxicity. Pharmacogenomics J 2002;2:43-47.
6. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with eto-
poside plus cisplatin for extensive small cell lung cancer. N Engl J Med 2002;346:85-
91.
7. Hanna N, Bunn P, Langer C, et al. Randomized phase III trial comparing irinotecan/
cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage 
disease small cell lung cancer. J Clin Oncol 2006;24:2038-2043.
8. Beutler E, Gelbart E, Demina A. Racial variability in the UDP-glucuronosyltransferase 
1 (UGT1A1) promote; a balanced polymorphism for regulation of bilirubin metabo-
lism? Proc Natl Acad Sci U S A 1998;95:8170-8174.
9. Font A, Taron M, Rosell R, et al. UGT1A1 genotyping correlates with toxicity and 
survival in non-small cell lung cancer (NSCLC) patients treated with second-line CPT-
11/docetaxel. Proc Am Soc Clin Oncol 2001;20:340a (abstract 1357).
10. Gandara D, Ohe Y, Kubota K, et al. Japan-SWOG common arm analysis of paclitaxel/
carboplatin in advanced non-small cell lung cancer (NSCLC): a model for prospec-
tive comparison of cooperative group trials. Proc Am Soc Clin Oncol 2004;22:618s 
(abstract 7007).
11. Han J, Lim H, Shin E, et al. Comprehensive analysis of UGT1A1 polymorphisms 
predictive for pharmacokinetics and treatment outcome in patients with non-small cell 
lung cancer treated with irinotecan and cisplatin. J Clin Oncol 2006;24:2237-2244.
12. Schmittel A, von Weikersthal L, Sebastian M, et al. A randomized phase II trial of 
irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with 
extended disease small-cell lung cancer. Ann Oncol 2006;17:663-667.
13. Briasoulis E, Samantas E, Kalofonos H, et al. Phase I study of etoposide, cisplatin, and 
irinotecan triplet in patients with advanced-stage small-cell lung cancer. Ca Chemother 
Pharm 2005;56:521-528.
14. Han J, Cho K, Lee D, et al. Phase II study of irinotecan plus cisplatin induction fol-
lowed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin che-
motherapy for limited-disease small-cell lung cancer. J Clin Oncol 2005;23:3488-3494.
15. Saito H, Takada Y, Ichinose Y, et al. Phase II study of etoposide and cisplatin with 
concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in 
patients with limited-disease small-cell lung cancer : West Japan Thoracic Oncology 
Group 9902. J Clin Oncol 2006;24:5247-5252.
Session E12: Recent Advances and Future 
Prospective in Lung Cancer Pathology 
E12-01 Recent Adv and Future Prospective in LC Pathology, Tue, Sept 4, 16:00 – 17:30
NCI Director’s challenge gene profiling of lung adenocarcinomas: 
impact on histologic classification
Travis, William D. 
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Despite the remarkable advances in the molecular biology of lung 
adenocarcinoma, surprisingly few studies are supported by carefully 
detailed pathologic data. Lung adenocarcinoma histologic subtyping 
continues to evolve following the 2004 WHO classiﬁcation. 1 The 
search for a clinically and biologically meaningful way to further 
characterize the mixed subtype adenocarcinomas needs to be based 
on careful attention to the histologic criteria being applied so the data 
can be compared to other studies. There are widely varying published 
results regarding the correlation of histologic subtypes with different 
molecular features including EGFR, k-RAS and gene expression proﬁl-
ing. The methods of some of these papers indicate varied pathologic 
deﬁnitions, suggesting that some of these differences may be attributed 
to interpretation of the histologic subtyping. Most articles also focus on 
a single subtype of lung adenocarcinoma, mostly bronchioloalveolar 
carcinoma (BAC), comparing this with all other adenocarcinomas. Fu-
ture molecular studies of lung adenocarcinoma should be accompanied 
by careful histologic subtyping of the tumors with attention not only to 
a single component such as BAC, but all histologic subtypes, noting the 
predominant pattern in mixed subtype tumors. 
Correlations between histology and molecular ﬁndings also vary de-
pending whether the study involves non-small cell carcinoma or purely 
adenocarcinoma. For example associations between EGFR mutations 
and non-smokers, female gender, Asian descent, and adenocarcinoma, 
particularly with BAC, are generally much stronger if all non-small cell 
carcinomas are studied. These correlations are often not as strong in 
studies of pure adenocarcinoma. 
While there is much emphasis in the literature about BAC and EGFR 
mutations, 2; 3 Tsao AS, Shigematsu H, Yoshida Y and Yatabe Y showed 
a lack of association of EGFR mutation with BAC subtype suggest-
ing an association with invasive adenocarcinoma rather than BAC. 4-7 
Kim, YH et al found that a dominant papillary subtype is a signiﬁcant 
predictor of response to geﬁtinib in adenocarcinoma of the lung. 8 K-ras 
mutations are associated with 73-100% of the mucinous type of BAC. 9
Gene proﬁling studies using cDNA arrays have consistently identiﬁed 
3-4 clusters among of lung adenocarcinomas. 10-12 This is a powerful 
tool that can measure the expression of thousands of genes in a single 
tumor sample, allowing for identiﬁcation of clinically and biologically 
subsets of tumors that are not apparent by usual clinical or pathologic 
methods. 13 Numerous studies have examined gene expression in a 
variety of subsets of lung cancer patients including non-small cell 
carcinoma, 14-20 adenocarcinoma, 10-12; 21-31 squamous cell carcinoma, 23; 
26; 32; 33 and small cell carcinoma. 34 Gene expression proﬁling of lung 
cancers has been used to identify sets of genes that predict prognosis, 
10; 17; 21; 25; 31; 32; 35-37 smoking status, 38 likelihood of metastases to lymph 
node15; 18; 29 or brain39, effectiveness of chemotherapy, 15; 40-42 tumor-stro-
mal interactions, 43; 44 and differential diagnosis with other tumors such 
as malignant mesothelioma. 45 In addition to cDNA microarrays, other 
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molecular assays such as serial analysis of gene expression (SAGE) 46 
and comparative genomic hybridization47-49 have provided valuable data 
about lung cancers.
Most gene proﬁling studies of lung adenocarcinoma have identi-
ﬁed several gene clusters that correlate with different phenotypes. In 
particular a subgroup of adenocarcinomas appears to correspond to pe-
ripheral airway differentiation. 11; 12; 31; 50 Other subsets are not as distinc-
tive, but in general the peripheral airway cluster correlates with EGFR 
mutation and TTF-1 expression. 12 The neuroendocrine subset identiﬁed 
by Bhattacharjee et al, may be in part due to contamination by large 
cell neuroendocrine carcinoma (LCNEC). Recent papers analyzing ei-
ther adenocarcinomas alone or non-small cell carcinomas overall have 
identiﬁed sets of genes that correlate with prognosis, however there is 
no consensus on which genes are predictive of outcome. 19; 51-53 
We are still awaiting studies that make correlations with detailed 
adenocarcinoma histologic subtyping and where other tumors such 
as LCNEC are reliably excluded. All 2004 WHO histologic subtypes 
of lung adenocarcinoma need to be assessed rather than just a single 
subtype such as BAC.
Reference List
1. Travis WD, Garg K, Franklin WA, et al. Evolving concepts in the pathology and com-
puted tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. 
J.Clin.Oncol. 2005; 23:3279-87.
2. Haneda H, Sasaki H, Shimizu S, et al. Epidermal growth factor receptor gene mutation 
deﬁnes distinct subsets among small adenocarcinomas of the lung. Lung Cancer. 2006; 
52:47-52.
3. Matsumoto S, Iwakawa R, Kohno T, et al. Frequent EGFR mutations in noninvasive 
bronchioloalveolar carcinoma. Int.J.Cancer. 2005; 118:2498-504.
4. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with 
epidermal growth factor receptor gene mutations in lung cancers. J.Natl.Cancer Inst. 
2005; 97:339-46.
5. Tsao A, Tang XM, Sabloff B, et al. Clinicopathologic characteristics of the EGFR gene 
mutation in non-small cell lung cancer. Journal of Thoracic Oncology 2006; 1:231-9.
6. Yatabe Y, Kosaka T, Takahashi T, Mitsudomi T. EGFR mutation is speciﬁc for terminal 
respiratory unit type adenocarcinoma. Am.J.Surg.Pathol. 2005; 29:633-9.
7. Yoshida Y, Shibata T, Kokubu A, et al. Mutations of the epidermal growth factor recep-
tor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the 
lung. Lung Cancer. 2005; 50:1-8.
8. Kim YH, Ishii G, Goto K, et al. Dominant papillary subtype is a signiﬁcant predictor of the 
response to geﬁtinib in adenocarcinoma of the lung. Clin.Cancer Res. 2004; 10:7311-7.
9. Wislez M, Beer DG, Wistuba I, Cadranel J, Saijo N, Johnson BE. Molecular Biology, 
Genomics, and Proteomics in Bronchioloalveolar Carcinoma. J Thorac Oncol 2006; 1:
S8-S12
10. Beer DG, Kardia SL, Huang CC, et al. Gene-expression proﬁles predict survival of 
patients with lung adenocarcinoma. Nat.Med. 2002; 8:816-24.
11. Bhattacharjee A, Richards WG, Staunton J, et al. Classiﬁcation of human lung carcino-
mas by mRNA expression proﬁling reveals distinct adenocarcinoma subclasses. Proc.
Natl.Acad.Sci.U.S.A 2001; 98:13790-5.
12. Takeuchi T, Tomida S, Yatabe Y, et al. Expression Proﬁle-Deﬁned Classiﬁcation of 
Lung Adenocarcinoma Shows Close Relationship With Underlying Major Genetic 
Changes and Clinicopathologic Behaviors. J.Clin.Oncol. 2006; 24:1679-88.
13. Ladanyi M, Gerald WL. Present and Potential Impact of Expression Proﬁling Studies 
of Human Tumors. Diagnostic and Research Applications. In: Ladanyi M, Gerald WL., 
eds. Expression proﬁling of Human Tumors. Totowa, NJ: Humana Press, 2003: 3-10.
14. Borczuk AC, Shah L, Pearson GD, et al. Molecular signatures in biopsy specimens of 
lung cancer. Am.J.Respir.Crit Care Med. 2004; 170:167-74.
15. Kikuchi T, Daigo Y, Katagiri T, et al. Expression proﬁles of non-small cell lung cancers 
on cDNA microarrays: identiﬁcation of genes for prediction of lymph-node metastasis 
and sensitivity to anti-cancer drugs. Oncogene 2003; 22:2192-205.
16. Mao Y, Wu J, Skog S, et al. Expression of cell proliferating genes in patients with non-
small cell lung cancer by immunohistochemistry and cDNA proﬁling. Oncol.Rep. 2005; 
13:837-46.
17. Parmigiani G, Garrett-Mayer ES, Anbazhagan R, Gabrielson E. A cross-study com-
parison of gene expression studies for the molecular classiﬁcation of lung cancer. Clin.
Cancer Res. 2004; 10:2922-7.
18. Takada M, Tada M, Tamoto E, et al. Prediction of lymph node metastasis by analysis of 
gene expression proﬁles in non-small cell lung cancer. J.Surg.Res. 2004; 122:61-9.
19. Tomida S, Koshikawa K, Yatabe Y, et al. Gene expression-based, individualized outcome 
prediction for surgically treated lung cancer patients. Oncogene 2004; 23:5360-70.
20. Yang P, Sun Z, Aubry MC, et al. Study design considerations in clinical outcome 
research of lung cancer using microarray analysis. Lung Cancer 2004; 46:215-26.
21. Berrar D, Sturgeon B, Bradbury I, Downes CS, Dubitzky W. Survival trees for analyz-
ing clinical outcome in lung adenocarcinomas based on gene expression proﬁles: 
identiﬁcation of neogenin and diacylglycerol kinase alpha expression as critical factors. 
J.Comput.Biol. 2005; 12:534-44.
22. Chen G, Bhojani MS, Heaford AC, et al. Phosphorylated FADD induces NF-kappaB, 
perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas. Proc.
Natl.Acad.Sci.U.S.A. 2005; 102:12507-12.
23. Doniels-Silvers AL, Nimri CF, Stoner GD, Lubet RA, You M. Differential gene expres-
sion in human lung adenocarcinomas and squamous cell carcinomas. Clin.Cancer Res. 
2002; 8:1127-38.
24. Giordano TJ, Shedden KA, Schwartz DR, et al. Organ-speciﬁc molecular classiﬁcation 
of primary lung, colon, and ovarian adenocarcinomas using gene expression proﬁles. 
Am.J.Pathol. 2001; 159:1231-8.
25. Gordon GJ, Richards WG, Sugarbaker DJ, Jaklitsch MT, Bueno R. A prognostic test 
for adenocarcinoma of the lung from gene expression proﬁling data. Cancer Epidemiol.
Biomarkers Prev. 2003; 12:905-10.
26. McDoniels-Silvers AL, Stoner GD, Lubet RA, You M. Differential expression of criti-
cal cellular genes in human lung adenocarcinomas and squamous cell carcinomas in 
comparison to normal lung tissues. Neoplasia. 2002; 4:141-50.
27. Singhal S, Amin KM, Kruklitis R, et al. Differentially expressed apoptotic genes in 
early stage lung adenocarcinoma predicted by expression proﬁling. Cancer Biol.Ther. 
2003; 2:566-71.
28. Wikman H, Kettunen E, Seppanen JK, et al. Identiﬁcation of differentially expressed 
genes in pulmonary adenocarcinoma by using cDNA array. Oncogene 2002; 21:5804-13.
29. Xi L, Lyons-Weiler J, Coello MC, et al. Prediction of lymph node metastasis by 
analysis of gene expression proﬁles in primary lung adenocarcinomas. Clin.Cancer Res. 
2005; 11:4128-35.
30. Yap YL, Wong MP, Zhang XW, et al. Conserved transcription factor binding sites of 
cancer markers derived from primary lung adenocarcinoma microarrays. Nucleic Acids 
Res. 2005; 33:409-21.
31. Garber ME, Troyanskaya OG, Schluens K, et al. Diversity of gene expression in adeno-
carcinoma of the lung. Proc.Natl.Acad.Sci.U.S.A 2001; 98:13784-9.
32. Sun Z, Yang P, Aubry MC, et al. Can gene expression proﬁling predict survival for 
patients with squamous cell carcinoma of the lung? Mol.Cancer. 2004; 3:35
33. Talbot SG, Estilo C, Maghami E, et al. Gene expression proﬁling allows distinction 
between primary and metastatic squamous cell carcinomas in the lung. Cancer Res. 
2005; 65:3063-71.
34. Bangur CS, Switzer A, Fan L, Marton MJ, Meyer MR, Wang T. Identiﬁcation of genes 
over-expressed in small cell lung carcinoma using suppression subtractive hybridization 
and cDNA microarray expression analysis. Oncogene 2002; 21:3814-25.
35. Blackhall FH, Wigle DA, Jurisica I, et al. Validating the prognostic value of marker 
genes derived from a non-small cell lung cancer microarray study. Lung Cancer 2004; 
46:197-204.
36. Volm M, Koomagi R, Mattern J, Efferth T. Expression proﬁle of genes in non-small cell 
lung carcinomas from long-term surviving patients. Clin.Cancer Res. 2002; 8:1843-8.
37. Wigle DA, Jurisica I, Radulovich N, et al. Molecular proﬁling of non-small cell lung 
cancer and correlation with disease-free survival. Cancer Res. 2002; 62:3005-8.
38. Miura K, Bowman ED, Simon R, et al. Laser capture microdissection and microarray 
expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-
related molecular proﬁles. Cancer Res. 2002; 62:3244-50.
39. Kikuchi T, Daigo Y, Ishikawa N, et al. Expression proﬁles of metastatic brain tumor 
from lung adenocarcinomas on cDNA microarray. Int.J.Oncol. 2006; 28:799-805.
40. Ohira T, Akutagawa S, Usuda J, et al. Up-regulated gene expression of angiogenesis 
factors in post-chemotherapeutic lung cancer tissues determined by cDNA macroarray. 
Oncol.Rep. 2002; 9:723-8.
41. Oshita F, Ikehara M, Sekiyama A, et al. Genomic-wide cDNA microarray screening to 
correlate gene expression proﬁle with chemoresistance in patients with advanced lung 
cancer. J.Exp.Ther.Oncol. 2004; 4:155-60.
42. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identiﬁes a death-from-
cancer signature predicting therapy failure in patients with multiple types of cancer. 
J.Clin.Invest. 2005; 115:1503-21.
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS256
43. Fromigue O, Louis K, Dayem M, et al. Gene expression proﬁling of normal human 
pulmonary ﬁbroblasts following coculture with non-small-cell lung cancer cells reveals 
alterations related to matrix degradation, angiogenesis, cell growth and survival. Onco-
gene 2003; 22:8487-97.
44. Nakamura N, Iijima T, Mase K, et al. Phenotypic differences of proliferating ﬁbroblasts 
in the stroma of lung adenocarcinoma and normal bronchus tissue. Cancer Sci. 2004; 
95:226-32.
45. Gordon GJ, Jensen RV, Hsiao LL, et al. Translation of microarray data into clinically 
relevant cancer diagnostic tests using gene expression ratios in lung cancer and meso-
thelioma. Cancer Res. 2002; 62:4963-7.
46. Fujii T, Dracheva T, Player A, et al. A preliminary transcriptome map of non-small cell 
lung cancer. Cancer Res. 2002; 62:3340-6.
47. Choi JS, Zheng LT, Ha E, et al. Comparative genomic hybridization array analysis 
and real-time PCR reveals genomic copy number alteration for lung adenocarcinomas. 
Lung. 2006; 184:355-62.
48. Hayashi M, Kawauchi S, Ueda K, et al. Genomic alterations detected by comparative 
genomic hybridization in primary lung adenocarcinomas with special reference to the 
relationship with DNA ploidy. Oncol Rep. 2005; 14:1429-35.
49. Shibata T, Uryu S, Kokubu A, et al. Genetic classiﬁcation of lung adenocarcinoma 
based on array-based comparative genomic hybridization analysis: its association with 
clinicopathologic features. Clin.Cancer Res. 2005; 11:6177-85.
50. Hayes DN, Monti S, Parmigiani G, et al. Gene expression proﬁling reveals reproducible 
human lung adenocarcinoma subtypes in multiple independent patient cohorts. J.Clin.
Oncol. 2006; 24:5079-90.
51. Chen HY, Yu SL, Chen CH, et al. A ﬁve-gene signature and clinical outcome in non-
small-cell lung cancer. N.Engl.J.Med. 2007; 356:11-20.
52. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to reﬁne prognosis in early-
stage non-small-cell lung cancer. N.Engl.J.Med. 2006; 355:570-80.
53. Raponi M, Zhang Y, Yu J, et al. Gene expression signatures for predicting prognosis of 
squamous cell and adenocarcinomas of the lung. Cancer Res. 2006; 66:7466-72.
E12-02 Recent Adv and Future Prospective in LC Pathology, Tue, Sept 4, 16:00 – 17:30
Cytology and fine needle aspiration biopsy in the diagnosis of lung 
cancer
Zakowski, Maureen F. 
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Conventional cytology such as sputum, bronchial brushes, washes 
and lavages and ﬁne needle aspiration biospy (FNA) have long played 
a role in the diagnosis of primary and metastatic lung cancers. The 
separation of small cell lung cancer from non small cell lung can-
cer (NSCLC), especially in cytologic material, has historically been 
deemed sufﬁcient for purposes of patient treatment. Small cell carcino-
ma was treated by chemotherapy and NSCLC underwent surgery ﬁrst 
and then chemotherapy where appropriate. The separation of NSCLC 
into adenocarcinoma and its subtypes and squamous cell carcinomas 
was not necessary. In the era of targeted therapy this approach is no 
longer adequate.
Cytologic preparations can allow the distinction of adenocarcinoma 
subtypes, particularly bronchioloalveolar, and the recognition of squa-
mous cell carcinoma.
The use of immunohistochemical stains such as TTF-1, CK7, CK20, 
4A4, 34βE12 and p63 can be applied to cytologic material to help 
make these distinctions. In additon, cytology material such as cells 
blocks can be utilzed for EGFR gene mutation studies.
Speciﬁc cytologic ﬁndings associated with the presence of BAC or 
adenocarcinoma with a BAC component can be identiﬁed in cytologic 
preparatins. These ﬁndings include ﬂat sheets of epithelial cells, nuclear 
inclusions and grooves and lack of prominent nucleoli.
The role of cytology in the diagnosis and management of lung cancer is 
of increasing importance and cytology can be used to provide excellent 
and accurate classiﬁcations of lung tumors. 
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Undertaking frozen sections (FSs) is a well-established and diagnosti-
cally accurate procedure that aids in the intra-operative staging of 
many cancers (1). The European Society of Thoracic Surgeons (ESTS) 
have recently published guidelines relating to intraoperative lymph 
node staging, and the pathologic evaluation of resected lymph nodes 
in patients with non-small cell lung cancer (NSCLC) with the aim of 
standardising management (2). A standardised approach to FS analysis 
of bronchial resection margins has also been recently proposed that 
highlights the difference between direct growth of invasive non-small 
cell carcinoma, lymphangitic spread and carcinoma-in situ (3)
In an effort to reﬁne the above, there have also been recent studies 
assessing whether identiﬁcation of sentinel nodes for frozen section 
may inﬂuence extent of resection and number of nodes required to be 
assessed during operation, with varying degrees of success (4,5).
The increased reﬁnement of adenocarcinoma diagnosis in relation to 
the patterns identiﬁed in the WHO classiﬁcation (6) and the Noguchi 
classiﬁcation (7) has also led to groups assessing how far this can be 
taken at FS, as limited resection could be an acceptable alternative for 
some patients with ÎearlyÌ disease. One study has shown that, in small 
(< or = 10 mm) peripheral adenocarcinomas, FS may be used to apply 
Noguchi’s classiﬁcation, particularly types A and B, in which there may 
be intent to limited surgery (8). Using imprint cytology, there are also 
cytological factors that can predict invasion in small-sized peripheral 
lung adenocarcinoma with a bronchioloalveolar carcinoma component. 
In one study, univariate analysis identiﬁed ﬁve cytologic factors that 
were associated signiﬁcantly with invasion (presence of tumour clusters 
comprising more than 50 tumour cells, nuclear overlap in more than 
three layers, presence of nuclear grooves, more than 3-fold variation 
in nuclear size, and 1 mitosis per 1000 tumour cells). Among these, 
nuclear overlapping in more than three layers and more than 3-fold 
variation in nuclear size were found to be independent predictive fac-
tors for invasion by multivariate analysis (9).
Another problem area, particularly in the lung, is when there is a his-
tory of previous malignancy. Differentiating primary from metastatic 
carcinomas can be difﬁcult, especially with poorer morphology on FS 
and no histological feature is 100% speciﬁc (10). In parafﬁn-embedded 
tissue, an immunohistochemical panel is typically used to in addition 
to morphology to assess cytokeratin proﬁles (e.g. 7 and 20) and the 
presence/absence of more organ-speciﬁcÌ epitopes such as thyroid tran-
scription factor-1 (TTF-1) and hormone receptors. Of these TTF-1 is 
the most valuable as it is highly speciﬁc and sensitive for primary lung 
tumours, excluding thyroid neoplasms (11,12). The ability to undertake 
intra-operative immunohistochemstry would therefore be of potential 
value as distinction of the type of tumour at this timepoint could inﬂu-
ence surgery (anatomic resection for primary lung cancer and more 
localised resection for metastatic disease) (13,14) and methodology that 
permits this within the timeframe of a thoracotomy and with similar 
speciﬁcity and sensitivity to that seen for formalin-ﬁxed tissues has 
recently become available (FSIHC) (15).
In a prospective study over two years, this additional immunohisto-
chemical data at the time of operation increased diagnostic conﬁdence 
in all cases, particularly in cases that were positive for TTF-1 (16). 
